CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Choon Ta, Gonzalez Bonilla, Hilda M., Chang, Ian, Aung, M. Tun, Gile, Jennifer J., Pereira, Naveen L., Villasboas Bisneto, Jose C., Johnston, Patrick B., Villarraga, Hector R., Rodriguez-Porcel, Martin G., Lin, Grace, Lin, Yi, Herrmann, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Mini-Focus Issue: Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240233/
https://www.ncbi.nlm.nih.gov/pubmed/37283829
http://dx.doi.org/10.1016/j.jaccas.2023.101840
Descripción
Sumario:Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupture, cardiac tamponade, and circulatory failure. We present a case series of patients with lymphoma and cardiomyopathy or cardiac metastasis managed with chimeric antigen receptor T-cell therapy. (Level of Difficulty: Advanced.)

Ejemplares similares